

(19) World Intellectual Property Organization  
International Bureau



(43) International Publication Date  
16 March 2006 (16.03.2006)

PCT

(10) International Publication Number  
WO 2006/028977 A2

(51) International Patent Classification:  
C07D 311/78 (2006.01) C07D 491/10 (2006.01)  
C07D 487/10 (2006.01)

(21) International Application Number:  
PCT/US2005/031341

(22) International Filing Date:  
1 September 2005 (01.09.2005)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:  
60/606,556 2 September 2004 (02.09.2004) US

(71) Applicant (for all designated States except US): THE  
PENN STATE RESEARCH FOUNDATION [US/US];  
304 Old Main Street, University Park, PA 16802 (US).

(72) Inventor; and

(75) Inventor/Applicant (for US only): ZHANG, Xumu  
[US/US]; 276 Camelot Lane, State College, PA 16803  
(US).

(74) Agent: GREELEY, Paul, D.; Ohlandt, Greeley, Ruggiero  
& Perle, L.L.P., One Landmark Square, 10th Floor, Stam-  
ford, CT 06901-2682 (US).

(81) Designated States (unless otherwise indicated, for every  
kind of national protection available): AE, AG, AL, AM,  
AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN,  
CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI,  
GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE,  
KG, KM, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA,  
MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ,  
OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL,  
SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC,  
VN, YU, ZA, ZM, ZW.


(84) Designated States (unless otherwise indicated, for every  
kind of regional protection available): ARIPO (BW, GH,  
GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM,  
ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM),  
European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI,  
FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT,  
RO, SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA,  
GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:

— without international search report and to be republished  
upon receipt of that report

For two-letter codes and other abbreviations, refer to the "Guid-  
ance Notes on Codes and Abbreviations" appearing at the begin-  
ning of each regular issue of the PCT Gazette.

(54) Title: CHIRAL SPIRO COMPOUNDS AND THEIR USE IN ASYMMETRIC CATALYTIC REACTIONS



(I)

(57) Abstract: The present invention provides a chiral ligand, represented by a formula or its enantiomer: formula (I) X and X' can be independently O, NH, NR, NCOR or S; each of Z<sub>1</sub>-Z<sub>7</sub> and Z<sub>1</sub>'-Z<sub>7</sub>' can be independently H, alkyl, aryl, substituted alkyl, substituted aryl, alkoxy, aryloxy, nitro, amide, aryoxide, halide, hydroxyl, carboxylate, heteroaryl, or a cyclic alkene, fused aryl, or cyclic ether group formed to from any two adjacent Z groups or any two adjacent Z' groups; Y and Y' can be independently OH, OR, NH<sub>2</sub>, NHR, NR<sub>2</sub>, SH, PR<sub>2</sub>, OPR<sub>2</sub>, NHPR<sub>2</sub>, OP(OR)<sub>2</sub>, COOH, COOK, CONHR, or a linking group formed from Y and Y' groups together. Processes of preparing these ligands, catalysts that employ them and methods of using the catalysts are also provided.



WO 2006/028977 A2

**CHIRAL SPIRO COMPOUNDS AND THEIR USE IN ASYMMETRIC  
CATALYTIC REACTIONS**

5

**BACKGROUND OF THE INVENTION**

10 **1. FIELD OF THE INVENTION**

The present invention relates to novel chiral ligands derived from new spiro compounds and their utilities in catalysts for applications in asymmetric catalysis. More particularly, the present invention relates to metal complexes of these chiral spiro ligands. The metal complexes according to the present invention are useful as catalysts in asymmetric reactions, such as hydrogenation, hydride transfer, allylic alkylation, alkylation, hydrosilylation, hydroboration, hydrovinylation, hydroformylation, olefin metathesis, hydrocarboxylation, Epoxidation, isomerization, cyclopropanation, Diels-Alder reaction, Heck reaction, isomerization, Aldol reaction, Michael addition; Mannich reaction, epoxidation, kinetic resolution, [m+n] cycloaddition and chiral Lewis acid catalyzed reactions.

25 **2. DESCRIPTION OF RELATED ART**

Discovery of new chiral ligands sets the foundation of highly enantioselective transition metal-catalyzed reactions. Many chiral ligands have been developed for asymmetric catalysis, however, only few chiral ligands or motifs are suitable for the synthesis of chiral molecules in industry and academic lab. Transition-metal catalyzed enantioselective hydrogenation is a powerful strategy to synthesize chiral substances from

30

unsaturated starting materials. Since DIOP ligand was discovered by Kagan in 1971 (Kagan, H. B.; Dang, T.-P. *Chem. Commun.* **1971**, 481. (b) Kagan, H. B.; Dang, T.-P. *J. Am. Chem. Soc.* **1972**, 94, 6429), a large number of bidentate ligands, especially those diphosphine ligands with C<sub>2</sub>-symmetry, have been developed for highly efficient asymmetric hydrogenation of various olefins, ketones, and imines. In comparison, monodentate ligands had been much less successful due to the conformational flexibility of their metal/ligand complexes. However, recent advances, indicated that monodentate ligands can be effective for asymmetric hydrogenation. For example, MonoPhos has been prepared from BINOL) (Claver, C.; Fernandez, E.; Gillon, A.; Heslop, K.; Hyett, D. J.; Martorell, A.; Orpen, A. G.; Pringle, P. G. *Chem. Commun.* **2000**, 961. Reetz, M. T.; Mehler, G. *Angew. Chem., Int. Ed. Engl.* **2000**, 39, 3889, Hua, Z.; Vassar, V. C.; Ojima, I. *Org. Lett.* **2003**, 5, 3831, Hulst, R.; de Vries, K.; Feringa, B. L. *Tetrahedron: Asymmetry* **1994**, 5, 699. Berg, M. v. d.; Minnaard, A. J.; Schudde, E. P.; Esch, J. v.; Vries, A. H. M. d.; Vries, J. G. d.; Feringa, B. L. *J. Am. Chem. Soc.* **2000**, 122, 11539. Pen, D.; Minnaard, A. J.; Vries, J. G. d.; Feringa, B. L. *J. Am. Chem. Soc.* **2002**, 124, 14552). Excellent enantioselectivities in Rh-catalyzed asymmetric hydrogenation of  $\alpha$ -,  $\beta$ -dehydroamino acid derivatives, itaconic acid derivatives, and enamides. Using 1,1-spirobiindane-7,7-diol (Birman, V. B.; Rheingold, A. L.; Lam, K.-C. *Tetrahedron: Asymmetry* **1999**, 10, 125), Zhou et.al. have prepared a series of spiro monodentate phosphoramidite ligands (SIPHOS), and good to excellent results ( Fu, Y.; Xie, J.-H.; Hu, A.-G.; Zhou, H.; Wang, L.-X.; Zhou, Q.-L. *Chem. Commun.* **2002**, 480. Hu, A.-G.; Fu, Y.; Xie, J.-H.; Zhou, H.; Wang, L.-X.; Zhou, Q.-L. *Angew. Chem. Int. Ed.* **2002**, 41, 2348. Zhu, S.-F.; Fu, Y.; Xie, J.-H.; Liu, B.; Xing, L.; Zhou, Q.-L. *Tetrahedron: Asymmetry* **2003**, 14, 3219. Fu, Y.; Guo, X.-X.; Zhu, S.-F.; Hu, A.-G.; Xie, J.-H.; Zhou, Q.-L. *J. Org. Chem.* **2004**, 69, 4648) have been achieved in asymmetric hydrogenation reactions (Figure

1). Despite this success, the method for making this spirodiol is too long and tedious and the application of these ligands and catalysts are limited.




Figure 1, Prior Art

5

In searching for new structural motifs, we found that 9,9'-spirobixanthene was first synthesized in the 1930s (Clarkson, R. G.; Gomberg, M. *J. Am. Chem. Soc.* **1930**, 52, 2881), and no further attempts had been made to assemble functional groups onto its aromatic rings. We therefore modified this spirocyclic framework into a new  $C_2$ -symmetrical 9,9'-spirobixanthene-1,1'-diol (Figure 2), which possesses larger biting angle and more rigid coordinating structure than BINOL. This new spirocyclic diol (**A**) is among the most accessible (in one case with only two-step synthesis) diols reported to date and can be made practically for many applications.

15





Figure 2 Examples

To demonstrate its potential role in asymmetric catalysis, spiro monodentate phosphoramidite ligand (**B**) (Figure 2) was prepared, which exhibited excellent enantioselectivity (up to 99% ee) in Rh-catalyzed asymmetric hydrogenation of  $\alpha$ -dehydroamino acid derivatives and itaconic acid.

### SUMMARY OF THE INVENTION

The present invention provides a compound represented by the formula or its enantiomer:




15

wherein X and X' are independently O, NH, NR, NCOR or S;  
 wherein each of Z<sub>1</sub>-Z<sub>7</sub> and Z'<sub>1</sub>-Z'<sub>7</sub> can be independently H, alkyl, aryl, substituted alkyl, substituted aryl, alkoxy, aryloxy, nitro, amide, aryoxide, halide, hydroxyl, carboxylate, heteroaryl, or a cyclic alkene,

fused aryl, or cyclic ether group formed from any two adjacent Z groups or any two adjacent Z' groups;


wherein Y and Y' are independently OH, OR, NH<sub>2</sub>, NHR, NR<sub>2</sub>, SH, PR<sub>2</sub>, OPR<sub>2</sub>, NHPR<sub>2</sub>, OP(OR)<sub>2</sub>, COOH, COOR, CONHR, or a linking group

5 formed from Y and Y' groups together and represented by the formula:



wherein W is NR<sub>2</sub>, NHR, R, OR, or a group represented by the formula:

10



wherein B is a divalent group can be (CH<sub>2</sub>)<sub>n</sub> wherein n is an integer from 1 to 6, 1,3-divalent phenyl, 2,2'-divalent-1,2'-biphenyl, 2,2'-divalent-1,1'biphenyl, 2,2'-divalent-1,1'-binaphthyl, ferrocene, or a substituted derivative thereof having one or more substituents each can be  
15 independently a linear, branched or cyclic alkyl of 1-8 carbon atoms, aryl

of 4-10 carbon atoms, F, Cl, Br, I, COOR, SO<sub>3</sub>R, hydroxy, OR, thiol, SR, aryloxy, nitro, phosphine, and NR<sub>2</sub>; and


wherein each R is independently selected from the group: a linear, branched or cyclic alkyl of 1-8 carbon atoms, substituted alkyl, aryl of 4-10  
5 carbon atoms, substituted aryl, aralkyl, and alkaryl, each R group optionally having one or more stereogenic centers.

The present invention further provides a catalyst prepared by a process including: contacting a transition metal, a salt thereof, or a  
10 complex thereof, and a ligand of the present invention wherein the contacting is carried out under reaction conditions sufficient to produce the catalyst.


The present invention still further provides a process for preparation  
15 of an asymmetric compound. The process includes the step of contacting a substrate capable of forming an asymmetric product by an asymmetric reaction and a catalyst prepared by a process including: contacting a transition metal, a salt thereof, or a complex thereof, and a ligand of the present invention, wherein the asymmetric reaction is can be  
20 hydrogenation, hydride transfer, allylic alkylation, hydrosilylation, hydroboration, hydrovinylation, hydroformylation, olefin metathesis, hydrocarboxylation, isomerization, cyclopropanation, Diels-Alder reaction, Heck reaction, isomerization, Aldol reaction, Michael addition, epoxidation, kinetic resolution and [m+n] cycloaddition wherein m = 3 to 6 and n = 2.

25

The present invention further still provides a process for preparation of a spirobixanthenediol ligand represented by the following formula:




or a ring-substituted derivative thereof, the process including the steps of:  
contacting a compound represented by the following formula:



5


or a ring-substituted derivative thereof with n-BuLi and thereafter with  
a compound represented by the following formula:



10


wherein the contacting is carried out at a temperature and length of time  
sufficient to produce a xanthene compound represented by the following  
formula:





or a ring-substituted derivative thereof;

contacting the xanthenol compound or a ring-substituted derivative  
 5 thereof and a mixture of concentrated hydrochloric acid and acetic acid at  
 a temperature and length of time sufficient to produce a dimethoxy  
 spirobixanthenone compound of the following formula:




10

or a ring-substituted derivative thereof;


contacting the dimethoxy spirobixanthenone compound or a ring-  
 substituted derivative thereof and pyridine hydrochloride at a temperature  
 15 and length of time sufficient to produce the spirobixanthenonediol  
 compound.

The present invention further still provides a second process for the  
 preparation of the above spirobixanthenonediol ligand or a ring-substituted  
 20 derivative thereof. The process includes the steps of:

contacting a compound represented by the following formula:



5 or a ring-substituted derivative thereof with n-BuLi and thereafter with an alkyl chloroformate at a temperature and length of time sufficient to produce a bis(2-methoxy-6-phenoxyphenyl)methanone compound represented by the following formula:



10

or a ring-substituted derivative thereof; and

15 contacting the bis(2-methoxy-6-phenoxyphenyl)methanone compound or a ring-substituted derivative thereof and aluminum chloride and thereafter with concentrated hydrochloric acid at a temperature and length of time sufficient to produce the spirobixanthenonediol compound.

20

**DETAILED DESCRIPTION OF THE INVENTION**

The preferred ligand compositions according to the present invention are shown below:

5





Figure 3 Ligand Invention

- 10 In these ligands, the bridge group X and X' for these ligands is O, NH, NR, NCOR and S, and R is an alkyl, aryl, substituted alkyl and aryl group. Z<sub>1</sub>-Z<sub>7</sub> and Z'<sub>1</sub>-Z'<sub>7</sub> are independently, H, alkyl, aryl, substituted alkyl, substituted aryl, alkoxy, aryloxy, nitro, amide, aryoxide, halide, hydroxyl, carboxylate, heteroaryl, or linked as a cyclic alkene, extended aryl group,
- 15 and cyclic ether. Y and Y' are independently, OH, OR, NH<sub>2</sub>, NHR, NR<sub>2</sub>, SH, PR<sub>2</sub>, OPR<sub>2</sub>, NHPR<sub>2</sub>, OP(OR)<sub>2</sub>, COOH, COOR, CONHR where R and R' are alkyl, aryl, substituted alkyl, substituted aryl or linked together as a biaryl group. In one case, W are NR<sub>2</sub>, NHR, R, OR, where R is an alkyl, aryl, substituted alkyl, substituted aryl, and these groups can have one or
- 20 more stereogenic centers.

In another case, W is as follows:



5

wherein B is  $(CH_2)_n$  where n is an integer ranging from 1 to 6, B is a divalent group selected from the group 1,3-divalent phenyl, 2,2'-divalent 1,2'-biphenyl, 2,2'-divalent -1,1'biphenyl, ferrocene, and a substituted derivative thereof; wherein each is selected from group: aryl, alkyl having  
 10 1-8 carbon atoms, F, Cl, Br, I, COOR, SO<sub>3</sub>R, OR, SR, aryloxy, nitro, NR<sub>2</sub> and combination thereof, wherein each R is independently selected from the group: alkyl, aryl, alkaryl and aralkyl.

Two pathways for making these types of compounds are listed  
 15 below. A key element is that X, Y or X', Y' both serves as ortho directing group to remove the proton in the aromatic ring between X and Y or X' and Y'. Some of these groups include O, OR, S, POR<sub>2</sub>, NCOR, NR, NR<sub>2</sub>, COOR, and CONR<sub>2</sub>.






Figure 4, General Synthesis Pathways

- 5 Chiral ligands having either enantiomers of ligands and a structure selected from the group:



In these ligands, the bridge group X and X' for these ligands is O, NH, NR, NCOR and S, and R is an alkyl, aryl, substituted alkyl and aryl group. Z<sub>1</sub>-Z<sub>7</sub> and Z'<sub>1</sub>-Z'<sub>7</sub> are independently, H, alkyl, aryl, substituted alkyl, substituted aryl, alkoxy, aryloxy, nitro, amide, aryoxide, halide, carboxylate, hydroxyl, heteroaryl, or linked as a cyclic alkene, extended aryl group, and cyclic ether. Y and Y' are independently, OH, OR, NH<sub>2</sub>, NHR, NR<sub>2</sub>, SH, PR<sub>2</sub>, OPR<sub>2</sub>, NHPR<sub>2</sub>, OP(OR)<sub>2</sub>, COOH, COOR, CONHR where R and R' are alkyl, aryl, substituted alkyl, substituted aryl or linked together as a biaryl group. In one case, W are NR<sub>2</sub>, NHR, R, OR, where R is an alkyl, aryl, substituted alkyl, substituted aryl, and these groups can have one or more stereogenic centers. In another case, W is as follows:


W =




15

wherein B is  $(\text{CH}_2)_n$  where n is an integer ranging from 1 to 6, B is a divalent group selected from the group: 1,3-divalent phenyl, 2,2'-divalent 1,2'-biphenyl, 2,2'-divalent -1,1'biphenyl, ferrocene, and a substituted derivative thereof; wherein each is selected from group: aryl, alkyl having 1-8 carbon atoms, F, Cl, Br, I, COOR, SO<sub>3</sub>R, OR, SR, aryloxy, nitro, NR<sub>2</sub> and combination thereof, wherein each R is independently selected from the group: alkyl, aryl, alkaryl and aralkyl.

In a preferred embodiment, the ligand above has following structure and its enantiomer



and




15

and W is NR<sub>2</sub>, NHR, R, OR, where R is an alkyl, aryl, substituted alkyl, substituted aryl, and these groups can have one or more stereogenic centers. Specially, W is Me, Et, CH<sub>2</sub>Ph, tBu, 2,6-dimethylphenyl, OCH<sub>3</sub>, OPh, 2,6-dimethylphenoxide, NMe<sub>2</sub>, NEt<sub>2</sub>, N(i-Pr)<sub>2</sub>, N(CH(CH<sub>3</sub>)Ph)<sub>2</sub>, NH(CH(CH<sub>3</sub>)Ph), N(CH<sub>3</sub>)(CH<sub>2</sub>Ph).

The process for making chiral spiro ligands through two pathways of racemic synthesis and resolution method. In this system, X, Y or X', Y'

both serves as ortho directing group to remove the proton in the aromatic ring between X and Y or X' and Y'. Some of these groups include O, OR, S, POR2, NCOR, NR, NR2, COOR, and CONR2.



Catalysts can be prepared with the ligands above with metals selected from the group: Cu, Ag, Au, Ni, Pt, Pd, Rh, Ru and Ir where ligands with at least phosphorus atom.

10

The transition metal salt, or complex thereof, is selected from the group: AgX; Ag(OTf); Ag(OTf)<sub>2</sub>; AgOAc; PtCl<sub>2</sub>; H<sub>2</sub>PtCl<sub>4</sub>; Pd<sub>2</sub>(DBA)<sub>3</sub>; Pd(OAc)<sub>2</sub>; PdCl<sub>2</sub>(RCN)<sub>2</sub>; (Pd(allyl)Cl)<sub>2</sub>; Pd(PR<sub>3</sub>)<sub>4</sub>; (Rh(NBD)<sub>2</sub>)X; (Rh(NBD)Cl)<sub>2</sub>; (Rh(COD)Cl)<sub>2</sub>; (Rh(COD)<sub>2</sub>)X; Rh(acac)(CO)<sub>2</sub>;



Rh(ethylene)<sub>2</sub>(acac); (Rh(ethylene)<sub>2</sub>Cl)<sub>2</sub>; RhCl(PPh<sub>3</sub>)<sub>3</sub>; Rh(CO)<sub>2</sub>Cl<sub>2</sub>;  
 RuHX(L)<sub>2</sub>(diphosphine), RuX<sub>2</sub>(L)<sub>2</sub> (diphosphine),  
 Ru(arene)X<sub>2</sub>(diphosphine), Ru(aryl group)X<sub>2</sub>; Ru(RCOO)<sub>2</sub>(diphosphine);  
 Ru(methylallyl)<sub>2</sub>(diphosphine); Ru(aryl group)X<sub>2</sub>(PPh<sub>3</sub>)<sub>3</sub>; Ru(COD)(COT);  
 5 Ru(COD)(COT)X; RuX<sub>2</sub>(cymen); Ru(COD)<sub>n</sub>; Ru(aryl  
 group)X<sub>2</sub>(diphosphine); RuCl<sub>2</sub>(COD); (Ru(COD)<sub>2</sub>)X; RuX<sub>2</sub>(diphosphine);  
 RuCl<sub>2</sub>(=CHR)(PR'<sub>3</sub>)<sub>2</sub>; Ru(ArH)Cl<sub>2</sub>; Ru(COD)(methylallyl)<sub>2</sub>; (Ir (NBD)<sub>2</sub>Cl)<sub>2</sub>;  
 (Ir(NBD)<sub>2</sub>)X; (Ir(COD)<sub>2</sub>Cl)<sub>2</sub>; (Ir(COD)<sub>2</sub>)X; CuX (NCCH<sub>3</sub>)<sub>4</sub>; Cu(OTf);  
 Cu(OTf)<sub>2</sub>; Cu(Ar)X; CuX; Ni(acac)<sub>2</sub>; NiX<sub>2</sub>; (Ni(allyl)X)<sub>2</sub>; Ni(COD)<sub>2</sub>; MnX<sub>2</sub>  
 10 and Mn(acac)<sub>2</sub>; wherein each R and R' is independently selected from the  
 group: alkyl or aryl; Ar is an aryl group; and X is a counteranion.

Rh-catalysts with ligands with at least one phosphorus atom are  
 suitable for hydrogenation olefins, imines, enamides and ketones.

15

The catalyst and catalyst precursor can be [Rh(COD)Cl]<sub>2</sub>,  
 [Rh(COD)<sub>2</sub>]X (X = BF<sub>4</sub>, ClO<sub>4</sub>, SbF<sub>6</sub>, CF<sub>3</sub>SO<sub>3</sub>, BAr<sub>4</sub> etc), [Ir(COD)Cl]<sub>2</sub>,  
 [Ir(COD)<sub>2</sub>]X (X = BF<sub>4</sub>, ClO<sub>4</sub>, SbF<sub>6</sub>, CF<sub>3</sub>SO<sub>3</sub>, etc) and chiral ligand with at  
 least one phosphorus atom. The catalysts can be  
 20 Ru(RCOO)<sub>2</sub>(diphosphine), RuX<sub>2</sub>(diphosphine) (X= Cl, Br, I),  
 Ru(methylallyl)<sub>2</sub>(diphosphine), Ru(aryl group)X<sub>2</sub>(diphosphine) and other  
 Ru catalysts with chiral ligands with at least one phosphorus atom.

The catalyst precursor can be [Rh(COD)Cl]<sub>2</sub>, [Rh(COD)<sub>2</sub>]X (X =  
 25 BF<sub>4</sub>, ClO<sub>4</sub>, SbF<sub>6</sub>, CF<sub>3</sub>SO<sub>3</sub>, BAr<sub>4</sub> etc), [Ir(COD)Cl]<sub>2</sub>, [Ir(COD)<sub>2</sub>]X (X = BF<sub>4</sub>,  
 ClO<sub>4</sub>, SbF<sub>6</sub>, CF<sub>3</sub>SO<sub>3</sub>, etc) and catalyst can be formed from catalyst  
 precursor and chiral ligands of the present invention such as those with at  
 least one phosphorus atom.

The catalysts can be  $\text{Ru}(\text{RCOO})_2(\text{diphosphine})$ ,  $\text{RuX}_2(\text{diphosphine})$  ( $X = \text{Cl}, \text{Br}, \text{I}$ ),  $\text{Ru}(\text{methylallyl})_2(\text{diphosphine})$ ,  $\text{Ru}(\text{aryl group})\text{X}_2(\text{diphosphine})$  and other Ru catalysts with chiral ligands with at least one phosphorus atom.

5

Catalyst with ligands of the present invention and transition metals, such as, rhodium, iridium, ruthenium, and palladium are used for asymmetric hydrogenation of ketones, imines, enamides and olefins.

10

The transition metal catalyzed asymmetric reactions with the catalysts of the present invention include hydrogenation, hydride transfer reaction, hydrosilylation, hydroboration, hydrovinylation, hydroformylation, hydrocarboxylation, allylic alkylation, cyclopropanation, Diels-Alder reaction, Aldol reaction, Heck reaction and Michael addition.

15

Rh, Ru, Ir, Pd compounds of the chiral ligands with at least one phosphorus atom are preferred.

The preferred catalysts are formed from  $[\text{Rh}(\text{COD})\text{Cl}]_2$ ,  $[\text{Rh}(\text{COD})_2]\text{X}$  ( $X = \text{BF}_4, \text{ClO}_4, \text{SbF}_6, \text{CF}_3\text{SO}_3$ , etc),  $[\text{Ir}(\text{COD})\text{Cl}]_2$ ,  $[\text{Ir}(\text{COD})_2]\text{X}$  ( $X = \text{BF}_4, \text{ClO}_4, \text{SbF}_6, \text{CF}_3\text{SO}_3$ , etc),  $\text{Rh}(\text{acac})(\text{CO})_2$ ,  $\text{Ni}(\text{allyl})\text{X}$  ( $X = \text{BF}_4, \text{ClO}_4, \text{SbF}_6, \text{CF}_3\text{SO}_3$ , etc),  $\text{Pd}_2(\text{dba})_3$ ,  $[\text{Pd}(\text{allyl})\text{Cl}]_2$ , and chiral ligands with at least one phosphorus atom.

25

Chiral Lewis acid catalysts with ligands with chiral diols are also preferred. The Lewis acid element can be Ti, Zr, Hf, Mg, Ca, B, Al, La-group elements, Ga, Mo, V, Li, Zn, Cu.


The catalyst precursor of Lewis acid compounds with the diols include  $\text{Ti}(\text{OR})_4$ ,  $\text{TiCl}_4$ ,  $\text{AlR}_3$ ,  $\text{AlCl}_3$ ,  $\text{Ti}(\text{Cl})_2(\text{OR})$ ,  $\text{Zr}(\text{OR})_4$ ,  $\text{MoO}_2(\text{acac})$ ,

30

VO(acac)<sub>2</sub>, La(OTf)<sub>3</sub>, La(OAc)<sub>3</sub>, Cu(OTf)<sub>2</sub>, n-BuLi, BH<sub>3</sub>, NaBH<sub>4</sub>, LiAlH<sub>4</sub>, BMe<sub>3</sub>, ZnEt<sub>2</sub>, MoNR(CHR)(OR)<sub>2</sub>, Mo(CO)<sub>6</sub>.

Such catalysts can be used for asymmetric alkylation, Diels-Alder  
 5 reaction, olefin metathesis, epoxidation, aldol reaction, Mannich reactions,  
 Michael addition and allylic alkylation.

10



15

9,9'-spirobixanthene-1,1'-diol (**3**) and its phosphoramidate compound (**4**)

20


Considering the  $C_2$  symmetric structure of **3**, we envisioned double cyclization of ketone would be one of efficient approaches.

Among the two possible ways (Scheme 1) to disconnect the  
 25 spirocyclic backbone into its ketone precursor, method **a** requires  
 protection with removable substituents of the positions *para* to the  
 methoxy groups in the aromatic ring before cyclization occurs.

On the other hand, there is no competing cyclization in method **b**.  
 30 Therefore, it is a preferred strategy to construct the designed spirocyclic  
 molecule.

Scheme 1. Retro synthetic analysis of **3**.

5




10 Starting from 3-phenoxyanisole (**1**), the symmetric ketone **2** was prepared in a moderate yield by linking two equivalents of lithiated **1** with methyl chloroformate (Scheme 2). Following treatment of **2** with an acid was expected to produce the spiran precursor **5**. However, several acidic reagents ( $\text{H}_2\text{SO}_4$ ,  $\text{HCl}$ , polyphosphoric acid, acetic acid, and trifluoroacetic acid)

15 acid) have been tested, and none of them can lead to the desired product. Interestingly, when we tried  $\text{AlCl}_3$ , target molecule **3** was formed directly.

As a Lewis acid,  $\text{AlCl}_3$  can promote not only Friedel-Craft alkylation but also deprotection of methyl ether. That accounts for the direct

20 formation of **3** from **2** in one pot.



5 Reagents and conditions: (a) (i) *n*-BuLi, THF, -78°C, (ii) ClCO<sub>2</sub>CH<sub>3</sub>, THF, -78°C; (b) (i) AlCl<sub>3</sub>, toluene, reflux, (ii) conc. HCl, reflux; (c) (i) *N*-benzylcinchonidinium chloride, acetonitrile; (ii) *N*-benzylquininium chloride, acetonitrile; (d) hexamethylphosphorous triamide, toluene, reflux.

10 To obtain enantiomerically pure **3**, co-crystallization of racemic **3** with chiral resolving reagents has been extensively studied. The most efficient reagent was found to be *N*-benzylcinchonidinium chloride (**6**), which can precipitate as co-crystals with one enantiomer of **3** in acetonitrile. X-ray diffraction of a single crystal grown from the precipitate  
 15 revealed a regularly packed molecular complex of **3** and **6** in 1:1 molar ratio. Based on the crystal structure of **6**, the absolute configuration of **3** is assigned to be (*R*). The other (*S*) enantiomer of **3** can be obtained from the mother solution by co-crystallization with *N*-benzylquininium chloride.

To make a clear presentation, some chiral ligands with this characteristics are listed. For each class of ligands, the corresponding enantiomer is also included.

- 5 These selective examples are used to illustrate the new chiral spiro compounds (L1-L41). These compounds can be prepared and used for asymmetric catalytic reactions (Figure 5- 8).




Figure 5. Examples




Figure 6. Examples




Figure 7. Examples






Figure 8. Examples

### General procedures

5

All reactions and manipulations were performed in a nitrogen-filled glovebox or using standard Schlenk techniques. THF and toluene were dried and distilled from sodium-benzophenone ketyl under nitrogen. Methylene chloride was distilled from  $\text{CaH}_2$ . Methanol was distilled from

Mg under nitrogen. (R, R)-BDNPB was made a solution of 10mg/ml in toluene before use.

Column chromatography was performed using EM silica gel 60  
5 (230~400 mesh).

$^1\text{H}$ ,  $^{13}\text{C}$  and  $^{31}\text{P}$  NMR were recorded on Bruker WP-200, AM-300, and AMX-360 spectrometers. Chemical shifts were reported in ppm down field from tetramethylsilane with the solvent resonance as the internal  
10 standard.

Optical rotation was obtained on a Perkin-Elmer 241 polarimeter. MS spectra were recorded on a KRATOS mass spectrometer MS 9/50 for LR-EI and HR-EI.

15

GC analysis was carried on Hewlett-Packard 6890 gas chromatography using chiral capillary columns.


HPLC analysis was carried on Waters<sup>TM</sup> 600 chromatography.

20

### Ligand Synthesis (pathway I)w

#### 1-methoxy-3-phenoxybenzene (a)

25



3-bromoanisole (470 g, 2.51 mol), phenol (292 g, 3.08 mol), copper  
30 (I) oxide (548 g, 3.83 mol), and potassium carbonate (190 g, 1.37 mol)

were refluxed with mechanic stirring at 190 °C for one hour, then cooled down. A small amount of phenol (50 g, 0.53 mol) was added, and then refluxed for 3 hours and 30 minutes, and then cooled down to room temperature.


5

CH<sub>2</sub>Cl<sub>2</sub> (1.5 L) was added into the reaction system, and stirred for 1 hour. The mixture was passed through a short Celite plug to remove insoluble substances. The residue on the plug was further washed with CH<sub>2</sub>Cl<sub>2</sub> (700 mL×3). The combined organic phase was washed with 2N NaOH (120 g in 1.5L water), brine (500 mL×2), dried over Na<sub>2</sub>SO<sub>4</sub>, and concentrated. Distillation under reduced pressure afforded the product as colorless liquid (440 g, yield 88%).

10

### 1-methoxyxanthen-9-one (b)

15



20


To the solution of **a** (246 g, 1.23 mol) in THF (1000mL) was added *n*-BuLi (2.5 M, 507 mL, 1.42 mol) by a 1000mL-dropping funnel at -78°C in 1.5 hour. After stirring at this temperature for 1 hour, it was stirred at room temperature for 1 hour. Then it was cooled to -78°C again, transferred via cannular into the solution of dimethylcarbamic chloride (113 mL, 1.23 mol) in THF (500mL) at -78°C. After stirring at this temperature for 1 hour, it was stirred at room temperature for another 4 hours. Meanwhile, LDA was prepared by adding *n*-BuLi (2.5 M, 1200 mL) slowly into diisopropylamine

25

(491 mL, 3.49 mol) in THF (2500mL) at -78°C. The prepared LDA solution was then stirred at -78°C for 15 minutes, followed by stirring at room temperature for 30 minutes. Then the intermediate solution prepared from **a** was added via cannular into LDA solution at 0°C, stirring overnight.

5

Aqueous HCl (3N, 1L) was introduced to quench the reaction at 0°C, stirred for 30 minutes so that phase separation occurred. The two layers were separated, the organic phase washed with brine, aqueous NaHCO<sub>3</sub> (saturated), and brine. The water layer was extracted with EtOAc, washed with aqueous NaHCO<sub>3</sub> (saturated), and brine. The combined organic solution was dried over Na<sub>2</sub>SO<sub>4</sub>, concentrated. EtOAc/hexane (1:9) was used to wash out impurities and afford product as light yellow powder (248 g, yield 89%).

15 **1-methoxy-9-(2-Methoxy-6-phenoxyphenyl) xanthen-9-ol (c)**


Lithiation of **a** (206 g, 1.03 mol) was achieved as described in step 2 (433 mL *n*-BuLi and 1000 mL THF was used), and the solution was then added into **b** (233 g) in THF (4000 mL) at -78°C within 1 hour, stirred overnight. Saturated NH<sub>4</sub>Cl solution (1 L) was used to quench the reaction at 0°C and a lot of solid appeared. A Celite plug was used to filter the solid.

25

The THF mother solution was concentrated, and the filtrate was washed with  $\text{CH}_2\text{Cl}_2$  (about 3.5 L). All the organic solution was combined, dried over  $\text{Na}_2\text{SO}_4$ , concentrated. Acetone was used to wash out impurity, giving the desired product as white powder (347 g, yield 79%).

5

**1,1'-Dimethoxy-9,9'-spirobixanthene (d)**




10

**d** (347 g, 0.81 mol), acetic acid (3000 mL), and concentrated HCl (2000 mL) were refluxed for 6 hours so that the original deep purple color faded to light pink. HOAc was removed under reduced pressure. The residue was dissolved in  $\text{CH}_2\text{Cl}_2$  (10 L), washed with saturated  $\text{NaHCO}_3$  solution, and brine, dried over  $\text{Na}_2\text{SO}_4$ , concentrated. Acetone (600 mL) was used to wash out impurity, giving the desired product as white powder (275 g, yield 83%).

20

**rac-9,9'-Spirobixanthenone-1,1'-diol (e)**




**d** (49 g, 0.13 mol) and pyridine-HCl (304 g, 2.63 mol) were heated to reflux for 25 minutes. The reaction mixture was diluted with HCl solution (4 N, 300 mL concentrated HCl in 600 mL water), extracted with EtOAc (1.5 L). The organic phase was further washed with HCl (4N) twice (450 mL each), then water (600 mL), saturated NaHCO<sub>3</sub> solution (500 mL), brine (500 mL), dried over Na<sub>2</sub>SO<sub>4</sub>. After EtOAc was removed, acetone (150 mL) was used to wash out impurity to get product as off white powder (32g, yield 70 %).

10

### Ligand Synthesis (Path Way II)

Synthesis of chiral monodentate spiro ligand via 9,9'-spirobixanthene-1,1'-diol.

15



Reagents and conditions: (a) (i) *n*-BuLi, THF, -78°C, (ii) ClCO<sub>2</sub>CH<sub>3</sub>, THF, -78°C; (b) (i) AlCl<sub>3</sub>, toluene, reflux, (ii) conc. HCl, reflux; (c) (i) *N*-benzylcinchonidinium chloride, acetonitrile; (ii) *N*-benzylquininium chloride, acetonitrile; (d) hexamethylphosphorous triamide, toluene, reflux.

20

**Bis(2-methoxy-6-phenoxyphenyl)methanone (2).**

To a solution of **1** (10.0 g, 25.0 mmol) in dry THF (80 mL) was slowly added *n*-BuLi (20 mL, 50 mmol, 2.5 M in hexane) at -78 °C within 15 minutes. The solution was stirred at -78 °C for 30 minutes, then at room temperature for two hours. The solution was then cooled to -78°C again, and transferred through a cannular into the solution of methyl chloroformate (1.94 mL, 25 mmol) in dry THF (40 mL) at -78 °C, then stirred overnight. The reaction was quenched by slowly adding 20 mL of aqueous NH<sub>4</sub>Cl (saturated) at 0 °C. The solvent THF was then removed under reduced pressure and the residue was extracted with EtOAc. The combined organic solution was washed with water and brine, dried over Na<sub>2</sub>SO<sub>4</sub>, and concentrated. The white precipitates were collected by filtration, and dried in vacuum to get **2** (6.6 g, 62% yield). <sup>1</sup>H-NMR (360 MHz, CD<sub>2</sub>Cl<sub>2</sub>) δ 3.69 (s, 6H, ArO-CH<sub>3</sub>), 6.39, 6.40 (d, 2H, *J*=8.3Hz, Ar-H), 6.61, 6.63 (d, 2H, *J*=8.3Hz, Ar-H), 6.76-6.79 (m, 4H, Ar-H), 7.01-7.05 (m, 2H, Ar-H), 7.16-7.25 (m, 6H, Ar-H); <sup>13</sup>C-NMR (91 MHz, CD<sub>2</sub>Cl<sub>2</sub>) δ 56.7, 107.1, 111.7, 119.1, 123.6, 124.7, 130.0, 131.7, 156.1, 157.7, 159.3, 191.9.

**(±)-9,9'-spirobixanthene- 1,1'-diol (3).**

To a solution of **2** (1.0 g, 2.3 mmol) in dry toluene (20 mL) was added AlCl<sub>3</sub> (1.9 g, 14.3 mmol). The solution was warmed slowly and refluxed for 30 minutes. Then it was cooled to 0°C and concentrated aqueous HCl (20 mL) was introduced with vigorous stirring. After refluxing for 1 hour, the reaction mixture was extracted with EtOAc, washed with concentrated HCl, water, aqueous NaHCO<sub>3</sub> and brine, dried over Na<sub>2</sub>SO<sub>4</sub>, and concentrated. Flash chromatography (eluting with CH<sub>2</sub>Cl<sub>2</sub>) gave **3** as light-yellow powder (0.64 g, yield 72%).

<sup>1</sup>H-NMR (360 MHz, CD<sub>2</sub>Cl<sub>2</sub>) δ 6.29, 6.31 (d, 2H, Ar-H), 6.59-6.61 (dd, 2H, *J*<sub>1</sub>=8.2Hz, *J*<sub>2</sub>=0.9Hz, Ar-H), 6.78-6.80 (m, 4H, Ar-H), 6.97-7.01 (m,

4H, Ar-H), 7.04-7.08 (m, 2H, Ar-H), 8.12 (s, 2H, Ar-OH);  $^{13}\text{C}$ -NMR (91 MHz,  $\text{CD}_2\text{Cl}_2$ )  $\delta$  38.5, 107.5, 111.0, 115.7, 116.6, 123.3, 127.8, 128.8, 131.7, 132.1, 150.2, 151.9, 156.7.

5 **Resolution of ( $\pm$ )-9,9'-spirobixanthene- 1,1'-diol (3).**

A suspension of racemic **3** (3.14 g, 8.26 mmol) and *N*-benzylcinchonidinium chloride **6** (1.84 g, 4.37 mmol) in acetonitrile (30 mL) was refluxed for 6 hours, then cooled slowly to room temperature overnight. The white solid (1:1 inclusion complex, 99.1% ee) was collected  
10 by filtration, then refluxed in acetonitrile (20 mL) for 6 hours, and cooled slowly to room temperature overnight. This precipitate was collected by filtration, washed twice with small amount of  $\text{CH}_3\text{CN}$  and dried in vacuum.

To a suspension of the purified 1:1 complex in ethyl acetate (30  
15 mL) was added 2N HCl (20 mL). The mixture was stirred until the entire solid was dissolved. The organic layer was separated, washed with 2N HCl (20 mL) and brine, dried over  $\text{Na}_2\text{SO}_4$ . Concentration under reduced pressure produced enantiomerically pure (*R*)-(+)-**3** (1.24 g, 79% yield, >99.9% ee).  $[\alpha]_{\text{D}}^{20} = +40.2$  ( $c = 1.0$ ,  $\text{CHCl}_3$ ).

20 The mother solution containing enriched *S* enantiomer was concentrated, and refluxed with *N*-benzylquininium chloride (1.97 g, 4.37 mmol) in acetonitrile (30 mL) for 6 hours. The clear solution was allowed to cool overnight. The precipitate was collected by filtration, washed with  
25 small amount of acetonitrile. Then it was added into EtOAc, washed with 2N HCl and brine, dried over  $\text{Na}_2\text{SO}_4$ . Concentration under reduced pressure produced enantiomerically pure (*S*)-(-)-**3** (1.22 g, 78% yield, 99.8% ee). The ee value was determined by HPLC on a Chiralcel AD-H column with isopropanol/hexane (4:96) as eluent.

30



**(*R*)-*O,O'*-(9,9'-spirobixanthene-1,1'-diyl)-*N,N*-dimethylphosphoramidate [(*R*)-4].**

To the solution of (*R*)-**3** (0.5 g, 1.32 mmol) in 10mL dry toluene was added hexamethylphosphorous triamide (287  $\mu$ L, 1.58 mmol). The solution was stirred at reflux for 72 hours. Then the toluene was removed under reduced pressure. Flash chromatography on silica gel with CH<sub>2</sub>Cl<sub>2</sub> afforded (*R*)-**4** as white powders. (0.21 g, 35%).

<sup>1</sup>H-NMR (360 MHz, CD<sub>2</sub>Cl<sub>2</sub>)  $\delta$  2.29 (s, 6H, -N(CH<sub>3</sub>)<sub>2</sub>), 6.33-6.35 (m, 1H, Ar-H), 6.43-6.45 (m, 1H, Ar-H), 6.72-6.75 (m, 1H, Ar-H), 6.84-6.89 (m, 2H, Ar-H), 7.03-7.07 (m, 2H, Ar-H), 7.11-7.15 (m, 2H, Ar-H), 7.21-7.25 (m, 2H, Ar-H), 7.39-7.48 (m, 2H, Ar-H); <sup>13</sup>C-NMR (91 MHz, CD<sub>2</sub>Cl<sub>2</sub>)  $\delta$  35.7 (d, *J*=15.5Hz, -N(CH<sub>3</sub>)<sub>2</sub>), 43.5 (s, C), 113.4 (s, C-H), 114.1 (d, *J*=2.6Hz, C-H), 117.2 (d, *J*=4.2Hz, 2(C-H)), 119.9 (s, C), 121.1-121.2(m, C-H), 121.6 (d, *J*=1.4Hz, C-H), 124.2 (d, *J*=1.7Hz, 2(C-H)), 126.5 (d, *J*=1.5Hz, 2(C-H)), 128.3 (s, C), 128.7 (s, C-H), 128.9 (d, *J*=2.7Hz, C-H), 129.7 (s, C-H), 129.9 (d, *J*=2.1Hz, C-H), 148.2 (d, *J*=4.1Hz, 2C), 150.3 (s, C), 150.4 (s, C), 151.6 (d, *J*=3.5Hz, 2C), 155.3 (s, C), 155.4 (s, C); <sup>31</sup>P-NMR (146 MHz, CD<sub>2</sub>Cl<sub>2</sub>)  $\delta$  123.2 (s).

20


**General Procedure of Hydrogenation**


A solution of [Rh(nbd)<sub>2</sub>]BF<sub>4</sub> (0.374 mg, 0.001 mmol) and ligand (*R*)-**3** (1.0 mg, 0.0022 mmol) in CH<sub>2</sub>Cl<sub>2</sub> (0.5 mL) was stirred in a glove-box for 10 min to allow the catalyst precursor to form. Then it was added into the solution of substrate (0.1 mmol) in 2.5 mL of CH<sub>2</sub>Cl<sub>2</sub>. Hydrogenation was performed in an autoclave with 25 psi of H<sub>2</sub> at room temperature for 12 hours. After releasing H<sub>2</sub>, the reaction mixture was passed through a short silica gel plug to remove the catalyst. The concentrated solution was used for chiral GC to measure the enantiomeric excess. For hydrogenation of itaconic acid, the ee was determined by its corresponding dimethyl ester.

30

**Table 1.** Rh(I)/(*R*)-4-catalyzed asymmetric hydrogenation of  $\alpha$ -dehydroamino acid derivatives and itaconic acid <sup>a</sup>

5



entry	substrate	ee (%) <sup>b</sup>	configuration <sup>c</sup>
1 <sup>d</sup>	R = H	98.2	S
2	R = Ph	98.4	S
3	R = <i>p</i> -F-Ph	99.9	S
4	R = <i>p</i> -Cl-Ph	99.1	S
5	R = <i>o</i> -Cl-Ph	99.3	S
6	R = <i>m</i> -Br-Ph	99.8	S
7	R = 2-naphthyl	99.8	S
8		97.9 <sup>e</sup>	S


<sup>a</sup> Refer to Experimental Section for details. All hydrogenation reactions were performed with 0.1mmol substrate and 0.001mmol in situ prepared [Rh(nbd)<sub>2</sub>]BF<sub>4</sub>/(*R*)-4 in CH<sub>2</sub>Cl<sub>2</sub> at room temperature, *P*<sub>H<sub>2</sub></sub> = 25psi. 100% conversion was observed within 12 hours. <sup>b</sup> Determined by chiral GC (Chirasil-VAL III FSOT). <sup>c</sup> The *S* absolute configuration was assigned by comparison of optical rotation with reported data. <sup>d</sup> THF/CH<sub>2</sub>Cl<sub>2</sub> (5:1) was used as solvent. <sup>e</sup> The ee was measured through its corresponding methyl ester (chiral GC, Gamma Dex-225).

The present invention has been described with particular reference to the preferred embodiments. It should be understood that the foregoing descriptions and examples are only illustrative of the invention. Various alternatives and modifications thereof can be devised by those skilled in the art without departing from the spirit and scope of the present invention. Accordingly, the present invention is intended to embrace all such alternatives, modifications, and variations that fall within the scope of the appended claims.


10

**WHAT IS CLAIMED IS:**


1. A compound represented by the formula or its enantiomer:



- 5            wherein X and X' are independently selected from the group  
 consisting of: O, NH, NR, NCOR and S;  
               wherein each of Z<sub>1</sub>-Z<sub>7</sub> and Z'<sub>1</sub>-Z'<sub>7</sub> is independently selected from the  
 group consisting of: H, alkyl, aryl, substituted alkyl, substituted aryl,  
 alkoxy, aryloxy, nitro, amide, aryoxide, halide, hydroxyl, carboxylate,  
 10    heteroaryl, and a cyclic alkene, fused aryl, or cyclic ether group formed  
 from any two adjacent Z groups or any two adjacent Z' groups;  
               wherein Y and Y' are independently selected from the group  
 consisting of: OH, OR, NH<sub>2</sub>, NHR, NR<sub>2</sub>, SH, PR<sub>2</sub>, OPR<sub>2</sub>, NHPR<sub>2</sub>, OP(OR)<sub>2</sub>,  
 COOH, COOR, CONHR, and a linking group formed from Y and Y' groups  
 15    together and represented by the formula:



wherein W is selected from the group consisting of: NR<sub>2</sub>, NHR, R, OR, and a group represented by the formula:



5

wherein B is a divalent group selected from the group consisting of: (CH<sub>2</sub>)<sub>n</sub> wherein n is an integer from 1 to 6, 1,3-divalent phenyl, 2,2'-divalent-1,2'-biphenyl, 2,2'-divalent-1,1'-biphenyl, 2,2'-divalent-1,1'-binaphthyl, ferrocene, and a substituted derivative thereof having one or more substituents each independently selected from the group consisting of: a linear, branched or cyclic alkyl of 1-8 carbon atoms, aryl of 4-10 carbon atoms, F, Cl, Br, I, COOR, SO<sub>3</sub>R, hydroxy, OR, thiol, SR, aryloxy, nitro, phosphine, and NR<sub>2</sub>; and

wherein each R is independently selected from the group: a linear, branched or cyclic alkyl of 1-8 carbon atoms, substituted alkyl, aryl of 4-10 carbon atoms, substituted aryl, aralkyl, and alkaryl, each R group optionally having one or more stereogenic centers.

2. The compound of claim 1, wherein said compound is a racemic mixture of enantiomers.

3. The compound of claim 1, wherein said compound is a non-racemic mixture of enantiomers.


5 4. The compound of claim 1, wherein said compound is one of the enantiomers.

5. The compound of claim 1, wherein said compound has an optical purity of at least 85% ee.

10

6. The compound of claim 1, wherein said compound has an optical purity of at least 95% ee.

7. The compound of claim 1, wherein said compound is  
15 represented by the formula or its enantiomer:




wherein X and X' are independently selected from the group consisting of: O, NH, NR, NCOR and S;

wherein each of Z<sub>1</sub>-Z<sub>7</sub> and Z'<sub>1</sub>-Z'<sub>7</sub> is independently selected from the group consisting of: H, alkyl, aryl, substituted alkyl, substituted aryl,  
 5 alkoxy, aryloxy, nitro, amide, aryoxide, halide, hydroxyl, carboxylate, heteroaryl, and a cyclic alkene, fused aryl, or cyclic ether group formed from any two adjacent Z groups or any two adjacent Z' groups;

wherein W is selected from the group consisting of: NR<sub>2</sub>, NHR, R, OR, and a group represented by the formula:

10



wherein B is a divalent group selected from the group consisting of:  
 (CH<sub>2</sub>)<sub>n</sub> wherein n is an integer from 1 to 6, 1,3-divalent phenyl, 2,2'-  
 15 divalent-1,2'-biphenyl, 2,2'-divalent-1,1'biphenyl, 2,2'-divalent-1,1'-  
 binaphthyl, ferrocene, and a substituted derivative thereof having one or  
 more substituents each independently selected from the group consisting  
 of: a linear, branched or cyclic alkyl of 1-8 carbon atoms, aryl of 4-10  
 carbon atoms, F, Cl, Br, I, COOR, SO<sub>3</sub>R, hydroxy, OR, thiol, SR, aryloxy,  
 20 nitro, phosphine, and NR<sub>2</sub>; and


wherein each R is independently selected from the group: a linear, branched or cyclic alkyl of 1-8 carbon atoms, substituted alkyl, aryl of 4-10 carbon atoms, substituted aryl, aralkyl, and alkaryl, each R group optionally having one or more stereogenic centers.

5


8. The compound of claim 8, wherein said compound has an optical purity of at least 85% ee.













9. The compound of claim 1, wherein said compound is represented by the formulae L1 - L43 or their enantiomers:












10












10. A catalyst prepared by a process comprising:  
 contacting a transition metal, a salt thereof, or a complex thereof,  
 and a ligand represented by the formula or its enantiomer:




5


wherein X and X' are independently selected from the group consisting of: O, NH, NR, NCOR and S;

wherein each of Z<sub>1</sub>-Z<sub>7</sub> and Z'<sub>1</sub>-Z'<sub>7</sub> is independently selected from the group consisting of: H, alkyl, aryl, substituted alkyl, substituted aryl,  
 10 alkoxy, aryloxy, nitro, amide, aryoxide, halide, hydroxyl, carboxylate, heteroaryl, and a cyclic alkene, fused aryl, or cyclic ether group formed from any two adjacent Z groups or any two adjacent Z' groups;

wherein Y and Y' are independently selected from the group consisting of: OH, OR, NH<sub>2</sub>, NHR, NR<sub>2</sub>, SH, PR<sub>2</sub>, OPR<sub>2</sub>, NHPR<sub>2</sub>, OP(OR)<sub>2</sub>,  
 15 COOH, COOR, CONHR, and a linking group formed from Y and Y' groups together and represented by the formula:



wherein  $W$  is selected from the group consisting of:  $\text{NR}_2$ ,  $\text{NHR}$ ,  $\text{R}$ ,  $\text{OR}$ , and a group represented by the formula:



5

wherein  $B$  is a divalent group selected from the group consisting of:  $(\text{CH}_2)_n$  wherein  $n$  is an integer from 1 to 6, 1,3-divalent phenyl, 2,2'-divalent-1,2'-biphenyl, 2,2'-divalent-1,1'-biphenyl, 2,2'-divalent-1,1'-binaphthyl, ferrocene, and a substituted derivative thereof having one or more substituents each independently selected from the group consisting of: a linear, branched or cyclic alkyl of 1-8 carbon atoms, aryl of 4-10 carbon atoms,  $\text{F}$ ,  $\text{Cl}$ ,  $\text{Br}$ ,  $\text{I}$ ,  $\text{COOR}$ ,  $\text{SO}_3\text{R}$ , hydroxy,  $\text{OR}$ , thiol,  $\text{SR}$ , aryloxy, nitro, phosphine, and  $\text{NR}_2$ ; and

wherein each  $\text{R}$  is independently selected from the group: a linear, branched or cyclic alkyl of 1-8 carbon atoms, substituted alkyl, aryl of 4-10 carbon atoms, substituted aryl, aralkyl, and alkaryl, each  $\text{R}$  group optionally having one or more stereogenic centers;

wherein said contacting is carried out under reaction conditions sufficient to produce said catalyst.


20

11. The catalyst of claim 10, wherein said ligand is a non-racemic mixture of enantiomers.

12. The catalyst of claim 10, wherein said ligand is one of the  
5 enantiomers.

13. The catalyst of claim 10, wherein said ligand has an optical purity of at least 95% ee.

10 14. The catalyst of claim 10, wherein said ligand is represented by the formula or its enantiomer:




15 wherein X and X' are independently selected from the group consisting of: O, NH, NR, NCOR and S;

wherein each of Z<sub>1</sub>-Z<sub>7</sub> and Z'<sub>1</sub>-Z'<sub>7</sub> is independently selected from the group consisting of: H, alkyl, aryl, substituted alkyl, substituted aryl,

alkoxyl, aryloxyl, nitro, amide, aryoxide, halide, hydroxyl, carboxylate, heteroaryl, and a cyclic alkene, fused aryl, or cyclic ether group formed from any two adjacent Z groups or any two adjacent Z' groups;

- wherein W is selected from the group consisting of: NR<sub>2</sub>, NHR, R,  
 5 OR, and a group represented by the formula:



10

- wherein B is a divalent group selected from the group consisting of: (CH<sub>2</sub>)<sub>n</sub> wherein n is an integer from 1 to 6, 1,3-divalent phenyl, 2,2'-divalent-1,2'-biphenyl, 2,2'-divalent-1,1'-biphenyl, 2,2'-divalent-1,1'-binaphthyl, ferrocene, and a substituted derivative thereof having one or  
 15 more substituents each independently selected from the group consisting of: a linear, branched or cyclic alkyl of 1-8 carbon atoms, aryl of 4-10 carbon atoms, F, Cl, Br, I, COOR, SO<sub>3</sub>R, hydroxy, OR, thiol, SR, aryloxyl, nitro, phosphine, and NR<sub>2</sub>; and

- wherein each R is independently selected from the group: a linear,  
 20 branched or cyclic alkyl of 1-8 carbon atoms, substituted alkyl, aryl of 4-10

carbon atoms, substituted aryl, aralkyl, and alkaryl, each R group optionally having one or more stereogenic centers.

15           15.    The catalyst of claim 10, wherein said transition metal is selected from the group consisting of:

Ag, Pt, Pd, Rh, Ru, Ir, Cu, Ni, Mo, Ti, V, Re and Mn.

16.    The catalyst of claim 10, wherein said transition metal is selected from the group consisting of:

10           Pt, Pd, Rh and Ru.

17.    The catalyst of claim 10, wherein said transition metal, salt thereof, or complex thereof, is selected from the group consisting of:

AgX; Ag(OTf); Ag(OTf)<sub>2</sub>; AgOAc; PtCl<sub>2</sub>; H<sub>2</sub>PtCl<sub>4</sub>; Pd<sub>2</sub>(DBA)<sub>3</sub>;  
 15 Pd(OAc)<sub>2</sub>; PdCl<sub>2</sub>(RCN)<sub>2</sub>; (Pd(allyl)Cl)<sub>2</sub>; Pd(PR<sub>3</sub>)<sub>4</sub>; (Rh(NBD)<sub>2</sub>)X; (Rh(NBD)Cl)<sub>2</sub>; (Rh(COD)Cl)<sub>2</sub>; (Rh(COD)<sub>2</sub>)X; Rh(acac)(CO)<sub>2</sub>;  
 Rh(ethylene)<sub>2</sub>(acac); (Rh(ethylene)<sub>2</sub>Cl)<sub>2</sub>; RhCl(PPh<sub>3</sub>)<sub>3</sub>; Rh(CO)<sub>2</sub>Cl<sub>2</sub>;  
 RuHX(L)<sub>2</sub>(diphosphine), RuX<sub>2</sub>(L)<sub>2</sub> (diphosphine),  
 Ru(arene)X<sub>2</sub>(diphosphine), Ru(aryl group)X<sub>2</sub>; Ru(RCOO)<sub>2</sub>(diphosphine);  
 20 Ru(methallyl)<sub>2</sub>(diphosphine); Ru(aryl group)X<sub>2</sub>(PPh<sub>3</sub>)<sub>3</sub>; Ru(COD)(COT);  
 Ru(COD)(COT)X; RuX<sub>2</sub>(cymene); Ru(COD)<sub>n</sub>; Ru(aryl group)X<sub>2</sub>(diphosphine); RuCl<sub>2</sub>(COD); (Ru(COD)<sub>2</sub>)X; RuX<sub>2</sub>(diphosphine);  
 RuCl<sub>2</sub>(=CHR)(PR'<sub>3</sub>)<sub>2</sub>; Ru(ArH)Cl<sub>2</sub>; Ru(COD)(methallyl)<sub>2</sub>; (Ir(NBD)<sub>2</sub>Cl)<sub>2</sub>;  
 (Ir(NBD)<sub>2</sub>)X; (Ir(COD)<sub>2</sub>Cl)<sub>2</sub>; (Ir(COD)<sub>2</sub>)X; CuX(NCCH<sub>3</sub>)<sub>4</sub>; Cu(OTf);  
 25 Cu(OTf)<sub>2</sub>; Cu(Ar)X; CuX; Ni(acac)<sub>2</sub>; NiX<sub>2</sub>; (Ni(allyl)X)<sub>2</sub>; Ni(COD)<sub>2</sub>;  
 MoO<sub>2</sub>(acac)<sub>2</sub>; Ti(OiPr)<sub>4</sub>; VO(acac)<sub>2</sub>; MeReO<sub>3</sub>; MnX<sub>2</sub> and Mn(acac)<sub>2</sub>;  
 wherein each R and R' is independently selected from the group consisting of: alkyl or aryl; Ar is an aryl group; and X is a counteranion.

30           18.    The catalyst of claim 17, wherein L is a solvent molecule and wherein said counteranion X is selected from the group consisting of:




halogen,  $\text{BF}_4$ ,  $\text{B}(\text{Ar})_4$  wherein the Ar in the  $\text{B}(\text{Ar})_4$  is fluorophenyl or 3,5-difluoromethyl-1-phenyl,  $\text{ClO}_4$ ,  $\text{SbF}_6$ ,  $\text{PF}_6$ ,  $\text{CF}_3\text{SO}_3$ ,  $\text{RCOO}$  and a mixture thereof .

5            19.    The catalyst of claim 10, prepared in situ or as an isolated compound.

              20.    A process for preparation of an asymmetric compound comprising:

10            contacting a substrate capable of forming an asymmetric product by an asymmetric reaction and a catalyst prepared by a process comprising: contacting a transition metal, a salt thereof, or a complex thereof, and a ligand represented by the formula or its enantiomer:

15




              wherein X and X' are independently selected from the group consisting of: O, NH, NR, NCOR and S;


20            wherein each of  $Z_1$ - $Z_7$  and  $Z'_1$ - $Z'_7$  is independently selected from the group consisting of: H, alkyl, aryl, substituted alkyl, substituted aryl,

alkoxyl, aryloxyl, nitro, amide, aryoxide, halide, hydroxyl, carboxylate, heteroaryl, and a cyclic alkene, fused aryl, or cyclic ether group formed from any two adjacent Z groups or any two adjacent Z' groups;

wherein Y and Y' are independently selected from the group consisting of: OH, OR, NH<sub>2</sub>, NHR, NR<sub>2</sub>, SH, PR<sub>2</sub>, OPR<sub>2</sub>, NHPR<sub>2</sub>, OP(OR)<sub>2</sub>, COOH, COOR, CONHR, and a linking group formed from Y and Y' groups together and represented by the formula:



wherein W is selected from the group consisting of: NR<sub>2</sub>, NHR, R, OR, and a group represented by the formula:



wherein B is a divalent group selected from the group consisting of: (CH<sub>2</sub>)<sub>n</sub> wherein n is an integer from 1 to 6, 1,3-divalent phenyl, 2,2'-divalent-1,2'-biphenyl, 2,2'-divalent-1,1'-biphenyl, 2,2'-divalent-1,1'-

binaphthyl, ferrocene, and a substituted derivative thereof having one or more substituents each independently selected from the group consisting of: a linear, branched or cyclic alkyl of 1-8 carbon atoms, aryl of 4-10 carbon atoms, F, Cl, Br, I, COOR, SO<sub>3</sub>R, hydroxy, OR, thiol, SR, aryloxy, nitro, phosphine, and NR<sub>2</sub>; and

wherein each R is independently selected from the group: a linear, branched or cyclic alkyl of 1-8 carbon atoms, substituted alkyl, aryl of 4-10 carbon atoms, substituted aryl, aralkyl, and alkaryl, each R group optionally having one or more stereogenic centers;

wherein said contacting is carried out under reaction conditions sufficient to produce said catalyst;

wherein said asymmetric reaction is selected from the group consisting of: hydrogenation, hydride transfer, allylic alkylation, hydrosilylation, hydroboration, hydrovinylation, hydroformylation, olefin metathesis, hydrocarboxylation, isomerization, cyclopropanation, Diels-Alder reaction, Heck reaction, isomerization, Aldol reaction, Michael addition, epoxidation, kinetic resolution and [m+n] cycloaddition wherein m = 3 to 6 and n = 2.

21. The process of claim 20, wherein said asymmetric reaction is hydrogenation and said substrate is selected from the group consisting of: imine, ketone, ethylenically unsaturated compound, enamine, enamide and vinyl ester.

22. The process of claim 20, wherein said asymmetric reaction is a silver-catalyzed asymmetric [3 +2] cycloaddition of an azomethine ylide with a dipolarophile.

23. The process of claim 20, wherein said asymmetric reaction is a palladium-catalyzed allylic alkylation and said substrate is an allylic ester.

24. The process of claim 20, wherein said asymmetric palladium-catalyzed allylic alkylation reaction is a kinetic resolution reaction and said substrate is a racemic allylic ester.


5

25. The process of claim 20, wherein said asymmetric reaction is hydrogenation, said substrate is a beta-ketoester, said transition metal is Ru and said asymmetric compound is a beta-hydroxyester.

10

26. The process of claim 20, wherein said asymmetric reaction is hydrogenation, said substrate is an enamide, said transition metal is Ru and said asymmetric compound is a beta amino acid.

27. The process of claim 20, wherein said ligand is represented  
15 by the formula or its enantiomer:




wherein X and X' are independently selected from the group consisting of: O, NH, NR, NCOR and S;

wherein each of Z<sub>1</sub>-Z<sub>7</sub> and Z'<sub>1</sub>'-Z'<sub>7</sub>' is independently selected from the group consisting of: H, alkyl, aryl, substituted alkyl, substituted aryl,  
 5 alkoxy, aryloxy, nitro, amide, aryoxide, halide, hydroxyl, carboxylate, heteroaryl, and a cyclic alkene, fused aryl, or cyclic ether group formed from any two adjacent Z groups or any two adjacent Z' groups;

wherein W is selected from the group consisting of: NR<sub>2</sub>, NHR, R, OR, and a group represented by the formula:

10




wherein B is a divalent group selected from the group consisting of: (CH<sub>2</sub>)<sub>n</sub> wherein n is an integer from 1 to 6, 1,3-divalent phenyl, 2,2'-  
 15 divalent-1,2'-biphenyl, 2,2'-divalent-1,1'-biphenyl, 2,2'-divalent-1,1'-binaphthyl, ferrocene, and a substituted derivative thereof having one or more substituents each independently selected from the group consisting of: a linear, branched or cyclic alkyl of 1-8 carbon atoms, aryl of 4-10  
 20 carbon atoms, F, Cl, Br, I, COOR, SO<sub>3</sub>R, hydroxy, OR, thiol, SR, aryloxy, nitro, phosphine, and NR<sub>2</sub>; and

wherein each R is independently selected from the group: a linear, branched or cyclic alkyl of 1-8 carbon atoms, substituted alkyl, aryl of 4-10

carbon atoms, substituted aryl, aralkyl, and alkaryl, each R group optionally having one or more stereogenic centers.


28. A process for the preparation of a spirobixanthenonediol  
5 ligand represented by the following formula:




or a ring-substituted derivative thereof, said process comprising the steps  
of:

contacting a compound represented by the following formula:


10



or a ring-substituted derivative thereof with *n*-BuLi and thereafter with  
a compound represented by the following formula:



wherein said contacting is carried out at a temperature and length of time sufficient to produce a xanthenol compound represented by the following formula:




5

or a ring-substituted derivative thereof;

contacting said xanthenol compound or a ring-substituted derivative thereof and a mixture of concentrated hydrochloric acid and acetic acid at a temperature and length of time sufficient to produce a dimethoxy spirobixanthenone compound of the following formula:

10



15

or a ring-substituted derivative thereof; and

contacting said dimethoxy spirobixanthenone compound or a ring-substituted derivative thereof and pyridine hydrochloride at a temperature and length of time sufficient to produce said spirobixanthenonediol compound.

20

29. The process of claim 28, wherein said ring-substituted derivative has one or more substituents each independently from the group consisting of: alkyl, aryl, substituted alkyl, substituted aryl, alkoxy, aryloxyl, nitro, amide, aryoxide, halide, hydroxyl, carboxylate, heteroaryl, and a cyclic alkene, fused aryl, or cyclic ether group formed from any two adjacent substituent groups.


30. The process of claim 28, further comprising:  
10 contacting said spirobixanthenediol compound or ring-substituted derivative thereof and *N*-benzylcinchonidinium chloride in a solvent to produce an 1:1 inclusion complex;  
purifying said 1:1 inclusion complex to produce enantiomerically pure (*R*)-(+)-spirobixanthenediol compound or ring-substituted derivative thereof and a mother liquor enriched in (*S*)-(-)-spirobixanthenediol  
15 compound or ring-substituted derivative thereof; and  
recovering said in (*S*)-(-)-spirobixanthenediol compound or ring-substituted derivative thereof from said mother liquor to produce enantiomerically pure (*S*)-(-)-spirobixanthenediol or ring-substituted  
20 derivative thereof.

31. The process of claim 30, wherein said ring-substituted derivative has one or more substituents each independently from the group consisting of: alkyl, aryl, substituted alkyl, substituted aryl, alkoxy, aryloxyl, nitro, amide, aryoxide, halide, hydroxyl, carboxylate, heteroaryl, and a cyclic alkene, fused aryl, or cyclic ether group formed from any two adjacent substituent groups.

32. The process of claim 30, further comprising:  
30 contacting said enantiomerically pure (*R*)-(+)-spirobixanthenediol compound or ring-substituted derivative thereof and



hexamethylphosphorous triamide at a temperature and length of time sufficient to produce (*R*)-*O,O'*-(9,9'-spirobixanthene-1,1'-diyl)-*N,N*-dimethylphosphoramidate ligand R-4 represented by the formula:




5

or a ring-substituted derivative thereof.

33. The process of claim 32, wherein said ring-substituted  
10 derivative has one or more substituents each independently from the group consisting of: alkyl, aryl, substituted alkyl, substituted aryl, alkoxy, aryloxy, nitro, amide, aryoxide, halide, hydroxyl, carboxylate, heteroaryl, and a cyclic alkene, fused aryl, or cyclic ether group formed from any two adjacent substituent groups.

15


34. A process for the preparation of a spirobixanthenediol ligand represented by the following formula:



or a ring-substituted derivative thereof, said process comprising the steps of:


contacting a compound represented by the following formula:

5



or a ring-substituted derivative thereof with n-BuLi and thereafter with an alkyl chloroformate at a temperature and length of time sufficient to produce a bis(2-methoxy-6-phenoxyphenyl)methanone compound

10 represented by the following formula:



or a ring-substituted derivative thereof;

15 contacting said bis(2-methoxy-6-phenoxyphenyl)methanone compound or a ring-substituted derivative thereof and aluminum chloride and thereafter with concentrated hydrochloric acid at a temperature and length of time sufficient to produce said spirobixanthenediol compound.

20 35. The process of claim 34, wherein said ring-substituted derivative has one or more substituents each independently from the group consisting of: alkyl, aryl, substituted alkyl, substituted aryl, alkoxy,

aryloxy, nitro, amide, aryoxide, halide, hydroxyl, carboxylate, heteroaryl, and a cyclic alkene, fused aryl, or cyclic ether group formed from any two adjacent substituent groups.